ストックスクリーナーアプリを入手
180.04
1.28%
-2.24
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca PLC (AZN) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know - Yahoo Finance Singapore
AstraZeneca PLC Stock (US6549022043): Obesity Drug Elecoglipron Heads Into Phase 3 As Shares Climb - AD HOC NEWS
ASTRAZENECA : Deutsche Bank maintains a Sell rating - marketscreener.com
ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations - Citeline News & Insights
Jim Cramer on AstraZeneca: “On Track to Hit the Ambitious Long-Term Financial Targets” - Yahoo Finance
Hansa Biopharma appoints Head of Business Development from AstraZeneca - marketscreener.com
AstraZeneca advances oral GLP-1 elecoglipron into phase 3 - MSN
AstraZeneca PLC stock (US6549022043): obesity drug data and pipeline momentum keep investors alert - AD HOC NEWS
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - Benzinga
Functional genomics and AI drive novel target discovery at AstraZeneca - Select Science
ASTRAZENECA : JP Morgan remains its Buy rating - marketscreener.com
ADA26: AstraZeneca unveils positive data for Phase III-ready oral GLP-1RA - Clinical Trials Arena
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth - GlobeNewswire Inc.
AstraZeneca Advances Obesity, Diabetes Medication Elecoglipron to Phase 3 Trial - marketscreener.com
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
NYLIM VP Income Builder Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
BofA reiterates Buy on AstraZeneca stock, cites adjuvant trial outlook By Investing.com - Investing.com South Africa
AstraZeneca progresses elecoglipron after positive phase IIb results - London South East
Why is CAMBRIA-1 emerging as AstraZeneca’s key breast cancer catalyst? - Investing.com Nigeria
ASTRAZENECA : Jefferies remains its Buy rating - marketscreener.com
AstraZeneca Gears Up for Phase 3 Trial of Weight-loss Drug - marketscreener.com
IAMS WEALTH MANAGEMENT, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results - GuruFocus
Elecoglipron cut nearly 12% of body weight in study, AstraZeneca says - AOL.com
AstraZeneca unveils data behind Phase III-bound oral GLP-1 - FirstWord Pharma
AstraZeneca’s oral GLP-1 advances to Phase III after strong trial results - Investing.com Nigeria
AstraZeneca obesity pill shows 10.5% weight loss in trial By Investing.com - Investing.com UK
AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio - marketscreener.com
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial - marketscreener.com
AstraZeneca advances weight-loss pill to take aim at obesity leaders - Financial Times
ADA 2026: AstraZeneca Advances Oral GLP-1 Elecoglipron Into Phase III After Positive Trial Data - Citeline News & Insights
AstraZeneca plc stock (GB0009895292): Oncology pipeline, obesity push and latest trial updates in fo - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential - DirectorsTalk Interviews
AstraZeneca hails phase 3 trial results of inhibitor Ultomiris - London South East
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
AstraZeneca warns it could delay Europe drug launchesFT - marketscreener.com
PRESS: AstraZeneca warns it could delay Europe drug launchesFT - London South East
AstraZeneca chief warns group could withhold new drugs in Europe - Financial Times
AstraZeneca Broadens US Growth Push - marketscreener.com
AstraZeneca advances Friday, outperforms market - MarketWatch
AstraZeneca plc stock (GB0009895292): Share price edges higher after 3.1% move and valuation focus - AD HOC NEWS
AstraZeneca (AZN) Stock Gains 3.1% as Bernstein Highlights Overlooked Non-Oncology Potential - parameter.io
AstraZeneca (AZN) Stock: Bernstein's £186 Target Highlights Overlooked Non-Oncology Potential - MoneyCheck
AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment - Blockonomi
AstraZeneca (AZN) Stock: Bernstein Sees 37% Upside as Non-Oncology Gets Ignored - CoinCentral
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History - Yahoo Finance
Bernstein: Why AstraZeneca’s biggest growth opportunity is being overlooked By Investing.com - Investing.com Nigeria
Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca - marketscreener.com
Why is AstraZeneca trending right now - Kalkine Media
AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 T - GuruFocus
AstraZeneca Advances New Fixed-Dose Cholesterol Pill Into Phase I: What Investors Should Watch - TipRanks
AstraZeneca advances Thursday, outperforms market - MarketWatch
AstraZeneca plc stock (GB0009895292): oncology growth and sector backdrop ahead of next earnings - AD HOC NEWS
AstraZeneca (AZN) CEO awarded 101,495 shares on AZPSP vesting - Stock Titan
AstraZeneca Sees Encouraging Survival Trend In Liver Cancer Trial - Yahoo
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum? - Yahoo Finance
Deutsche Bank Holds Sell Rating On AstraZeneca (LSE:AZN, NASDAQ:AZN) At 11,500p Despite Positive ASCO Data - londoninsider.co.uk
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions - Proactive financial news
AstraZeneca PLC Share PriceAZN, RNS News, Articles, Quotes, & Charts (LON:AZN) - Proactive Investors
0.28%
0.38%
大文字化:
|
ボリューム (24 時間):